ReviewCureus2025
Pulmonary Arterial Hypertension: Recognition and Management in Primary and Acute Care Settings.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a rare but life-threatening condition marked by progressive elevation in pulmonary vascular resistance and right ventricular failure. Because symptoms, most commonly progressive exertional dyspnea, overlap with more common cardiopulmonary disorders, diagnosis is frequently delayed. Primary and acute care clinicians are often the first to evaluate these patients, placing them in a key position to recognize early clues and initiate appropriate evaluation. This review provides practical, evidence-based guidance for the frontline assessment of suspected PAH. Historical features such as exertional dyspnea out of proportion to known disease, unexplained fatigue, syncope, or chest discomfort should raise concern, particularly in patients with connective tissue disease or other risk factors. Initial evaluation involves common tests for evaluating cardiopulmonary complaints: electrocardiography, chest radiography, and measurement of B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP). Transthoracic echocardiography is the most helpful initial imaging modality for estimating pulmonary artery pressures and assessing right ventricular structure and function. Definitive diagnosis, however, requires right heart catheterization, preferably at an accredited pulmonary hypertension (PH) center; empiric initiation of PAH-specific therapy is not recommended. By recognizing key clinical features, safeguarding ongoing therapy, and ensuring timely referral to PH centers, frontline clinicians may reduce diagnostic delays and improve outcomes for patients with PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.